

1. (ORIGINAL) A protein comprising the same or substantially the same amino acid sequence as an amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 14 or SEQ ID NO: 104, or a salt thereof.
2. (ORIGINAL) A protein consisting of an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 14, or a salt thereof.
3. (ORIGINAL) A protein consisting of an amino acid sequence represented by SEQ ID NO: 104, or a salt thereof.
4. (ORIGINAL) A partial peptide of the protein according to claim 1, or a salt thereof.
5. (AMENDED) A polynucleotide comprising a polynucleotide encoding the protein according to claim 1 or the partial peptide thereof according to claim 4.
6. (ORIGINAL) The polynucleotide according to claim 5, which is DNA.
7. (ORIGINAL) A DNA consisting of a base sequence represented by SEQ ID NO: 2, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 105 or SEQ ID NO: 112.
8. (ORIGINAL) A recombinant vector comprising the polynucleotide according to claim 5.
9. (ORIGINAL) A transformant transformed with the recombinant vector according to claim 8.
10. (AMENDED) A method of manufacturing a the protein having an amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 14 or SEQ ID NO: 104 or its salt according to claim 1 or the partial peptide or its salt according to claim 4 thereof, which comprises culturing the transformant according to claim 9, forming and accumulating the said protein according to claim 1 or the partial peptide thereof according to claim 4, and recovering it.
11. (AMENDED) A medicine pharmaceutical composition comprising the protein according to claim 1 or the partial peptide according to claim 4 thereof, and a pharmaceutically acceptable carrier, excipient or diluent.
12. (AMENDED) A medicine pharmaceutical composition comprising the polynucleotide according to claim 5 and a pharmaceutically acceptable carrier, excipient or diluent.
13. (AMENDED) An antibody to the protein according to claim 1, the partial peptide thereof according to claim 4, or a salt of the protein or partial peptide.

14. (AMENDED) A ~~medicine~~ pharmaceutical composition comprising the antibody according to claim 13 and a pharmaceutically acceptable carrier, excipient or diluent.

15. (ORIGINAL) A diagnostic agent comprising the antibody according to claim 13.

16. (ORIGINAL) A polynucleotide comprising a base sequence complementary or substantially complementary to the base sequence of the polynucleotide according to claim 5 or a part of the base sequence.

17. (AMENDED) A ~~medicine~~ pharmaceutical composition comprising the polynucleotide according to claim 16 and a pharmaceutically acceptable carrier, excipient or diluent.

18. (AMENDED) A method of screening a compound or its salt that promotes or inhibits the activity of the protein or its salt according to claim 1 or the partial peptide or its salt thereof ~~according to claim 4~~, which comprises using the protein or its salt according to claim 1 or the partial peptide or its salt ~~according to claim 4~~ thereof in a screening assay.

19. (AMENDED) The screening method according to claim 18, wherein the activity of the protein or its salt according to claim 1 or the partial peptide or its salt thereof ~~according to claim 4~~ is the substrate transport activity of the protein.

20. (AMENDED) A kit for screening a compound or its salt that promotes or inhibits the activity of the protein or its salt according to claim 1 or the partial peptide or its salt thereof ~~according to claim 4~~, which comprises the protein or its salt according to claim 1 or the partial peptide or its salt thereof ~~according to claim 4~~.

21. (CANCELED)

22. (CANCELED)

23. (AMENDED) A method of screening a compound or its salt that promotes or inhibits the expression of a gene for the protein according to claim 1, which comprises using ~~the~~ a polynucleotide encoding for said protein, or partial peptide thereof, in a screening assay ~~according to claim 5.~~

24. (AMENDED) A kit for screening a compound or its salt that promotes or inhibits the expression of a gene for the protein according to claim 1, which comprises ~~the~~ a polynucleotide encoding for said protein, or partial peptide thereof. ~~according to claim 5~~

25. (CANCELED)

26. (CANCELED)

27. (AMENDED) ~~The medicine according to claim 11, claim 12, claim 14, claim 17, claim 22 or claim 26, which is a prophylactic/therapeutic agent for~~ A method for making a pharmaceutical composition for treating or preventing hyperlipemia, arteriosclerosis, genital diseases or digestive diseases, said method comprising combining a therapeutic amount of at least one component selected from the group consisting of:

- i) a protein according to claim 1 or the partial peptide;
- ii) a polynucleotide encoding for the protein or partial peptide of claim 1;
- iii) an antibody to the protein according to claim 1, the partial peptide thereof;

and

iv) a polynucleotide comprising a base sequence complementary or substantially complementary to the base sequence of the polynucleotide encoding for the protein of claim 1, or the partial peptide thereof;

and a pharmaceutically acceptable carrier, excipient or diluent.

28. (AMENDED) ~~A method for treating or preventing prophylactic/therapeutic method for~~ hyperlipemia, arteriosclerosis, genital diseases or digestive diseases, which comprises administering an effective amount of at least one therapeutic selected from the group consisting of: a protein according to claim 1 or the partial peptide; a polynucleotide encoding for the protein or partial peptide of claim 1; an antibody to the protein according to claim 1, the partial peptide thereof; and a polynucleotide comprising a base sequence complementary or substantially complementary to the base sequence of the polynucleotide encoding for the protein of claim 1, or the partial peptide thereof;

~~the compound or its salt according to claim 21 or 25 into~~ to a mammal in need thereof.

29. – 115. (CANCELED)